Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03465592 · ClinicalTrials.gov registry record · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
A Phase 1 study of Sarcoma and Solid Tumor, Adult, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 4
- Study locations
NCT03465592: Recruiting Phase 1 study of Sarcoma and Solid Tumor, Adult, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT03465592 is a Phase 1 study of Sarcoma and Solid Tumor, Adult that is actively recruiting participants, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 39 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03465592, a Phase 1 study of Sarcoma and Solid Tumor, Adult, is actively recruiting participants, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 4
- Study locations
Study Summary
This research is being done to find out if an investigational drug, Nivolumab, can be safely administered after a "half-matched" (haplo) bone marrow transplant (BMT), and if the investigational drug will help to prevent or delay relapse or progression of sarcomas. In this study investigators will also be trying to learn more about how the investigational drug changes blood and/or tumors. Participants are eligible for this trial if they have recently undergone a "half-matched" (haplo) bone marrow transplant and have either relapsed or are at high risk to relapse.
Primary Outcome
Cumulative adverse events from Nivolumab therapy administered after reduced intensity conditioning (RIC) haploidentical bone marrow transplant (haploBMT) in children and young adults with high risk sarcomas at the time of relapse (part A) or pre-emptively (part B).
Conditions Studied
Interventions
- DRUG Nivolumab
Study Locations (4)
New York
- Albert Einstein College of Medicine, Children's Hospital at Montefiore - The Bronx
- New York Medical Center/ Maria Fareri Children's Hospital - Valhalla
Florida
- Johns Hopkins All Children's Hospital - St. Petersburg
Maryland
- Johns Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2029-03 |
| Phase | Phase 1 |
What NCT03465592 shows while recruiting
NCT03465592 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Nivolumab is the first listed.
NCT03465592 reports a single indexed study location in New York, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT03465592 about?
NCT03465592 is a clinical study titled "Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma". This research is being done to find out if an investigational drug, Nivolumab, can be safely administered after a "half-matched" (haplo) bone marrow transplant (BMT), and if the investigational drug will help to prevent or delay relapse or progression of sarcomas. In this study investigators will al...
What is the current status of trial NCT03465592?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2018-05-01. Estimated completion is 2029-03.
What conditions does trial NCT03465592 study?
This clinical trial studies the following conditions: Sarcoma, Solid Tumor, Adult, Solid Tumor, Childhood.
What interventions are being tested in trial NCT03465592?
The interventions under investigation include: Nivolumab (DRUG).
Who is sponsoring clinical trial NCT03465592?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03465592 being conducted?
This trial has 4 study locations across Florida, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03465592's enrollment target sits among peer trials
39 78th of 122 higher than 45 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Palbociclib and Pembrolizumab in Sarcoma
RECRUITING · Phase 1
-
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
RECRUITING · Phase 1
-
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
- NCT04588545 · 39 participants · Phase 1
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy